Erin M. Taylor
Role not yet determined Is this you? Add your title
Also affiliated: Brigham and Women's Hospital (2019–2025); National Institutes of Health (2010); Beth Israel Deaconess Medical Center (2017–2021); Mount Sinai Hospital (2015); NewYork–Presbyterian Hospital (2013–2018); Harvard University (2017–2025); University of California, Los Angeles (2010); University of Dundee (2010); Cornell University (2014); University of Exeter (2025); University of Michigan (2015); Royal Derby Hospital (1990); Columbia University Irving Medical Center (2013–2018); Leicester Royal Infirmary (1988); American Society of Plastic Surgeons (2015); New York Hospital Queens (2013–2014); Freeman Hospital (2024); Johns Hopkins University Applied Physics Laboratory (2011); Massachusetts General Hospital (2020); University of Texas Health Science Center at Dallas (2016); Mount Sinai Medical Center (2015); Presbyterian Hospital (2014); Musculoskeletal Transplant Foundation (2019); Mount Sinai Hospital (2015); National Institute of Neurological Disorders and Stroke (2010); Michigan United (2015); North Middlesex Hospital (1992); Rush University (2017); Columbia University (2015); Icahn School of Medicine at Mount Sinai (2015)
Formerly Arkansas Affiliated with UAMS through 2019; recent publications list Brigham and Women's Hospital, Harvard University.
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Erin M. Taylor's research has explored diverse areas within health sciences, with a recent focus on cancer-related molecular mechanisms and immune responses. Publications include work on the role of E-Cadherin in melanoma's response to immune checkpoint inhibitors and the identification of progenitor cells in allergic diseases. Taylor also has experience in drug delivery systems, as indicated by research on nanoemulsion-based vaccine adjuvants. Other research interests include pain management and inflammation, with a study on pulsed electromagnetic fields, and health risk factors among homeless populations. Taylor's work is supported by collaborations with researchers at the University of Arkansas for Medical Sciences, including Brian Koss, Ricky D. Edmondson, Aaron J. Storey, and Samrat Roy Choudhury.
Metrics
- h-index: 15
- Publications: 57
- Citations: 784
Selected Publications
-
Abstract 4622: Proteomic insights into anti-CTLA4 therapy resistance in metastatic melanoma: Pathway-specific biomarkers for treatment response (2025)
-
CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells (2023)
-
Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness (2020)
-
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion (2020)
-
Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression (2020)
-
Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion (2020)
-
Histone Modifications as Biomarkers for Immunotherapy (2019)
-
Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma (2019)
-
Quantitative microinjection using fluorescence calibration of streaming microdroplets on a superhydrophobic surface (2018)
-
Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors (2017)
-
Indicators of responsiveness to immune checkpoint inhibitors (2017)
Collaboration Network
Top Collaborators
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Histone Modifications as Biomarkers for Immunotherapy
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
Showing 5 of 10 shared publications
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Histone Modifications as Biomarkers for Immunotherapy
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
Showing 5 of 8 shared publications
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression
- Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness
Showing 5 of 7 shared publications
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
Showing 5 of 6 shared publications
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
- Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression
- Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
- Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness
- Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness
- Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
- Indicators of responsiveness to immune checkpoint inhibitors
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
- Indicators of responsiveness to immune checkpoint inhibitors
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
- Indicators of responsiveness to immune checkpoint inhibitors
- Abstract LB-206: Indicators of responsiveness to immune checkpoint inhibitors
- Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
- Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion
Similar Researchers
Based on overlapping research topics